NFE2L2 and non-small cell lung carcinoma: Co‐mutations within the Kelch‐like ECH‐associated protein 1 (KEAP1)‐nuclear factor erythroid 2‐related factor 2 (NRF2) pathway, such as those in KEAP1, nuclear factor erythroid‐derived 2‐like 2 (NFE2L2), and Cullin 3 (CUL3), have also been reported to contribute to chemotherapy resistance and enhanced cell proliferation, worsening the prognosis of NSCLC [3].